LUD 5466.4 CIP - JEL/NDH

Now only claims 89-95 are pending. Claim 89 is corrected. Thus, the issues set forth in the advisory action are addressed.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.

Norman D. Hanson, Esq. Registration No. 30,946

666 Fifth Avenue New York, New York 10103-3198

Telephone: 212-318-3168 Telecopier: 212-318-3400

•	Application No.	Applicanius)		
Advisory Action	09/165,546	ALEXANDER ET AL.		
	Examiner	Art Unit		
	Amy M. DeCloux	1644		
-The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence address		
THE REPLY FILED 24 July 2002 FAILS TO PLACE THIS Therefore, further action by the applicant is required to available final rejection under 37 CFR 1.113 may only be either: (1 condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.	old abandonment of this application a timely filed amendment which (with appeal fee); or (3) a timely	n places the application in		
	EPLY [check either a) or b)]	•		
 a)	e of the final rejection.	in the final miection, whichever is later, in		
no event, however, will the statutory period for reply expire a ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of the under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Offic timely filed, may reduce any samed patent term adjustment. See 37 CFR 1.17(a) is calculated from adjustment.	ater than SIX MONTHS from the malling FILED WITHIN TWO MONTHS OF The date on which the petition under 37 CF of extension and the corresponding amount shortened statutory period for reply see later than three months after the mall	R 1.136(a) and the appropriate extension unt of the fee. The appropriate extension originally set in the final Office action; or		
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFI	Brief must be filed within the per R 1.191(d)), to avoid dismissal o	eriod set forth in f the appeal.		
2. The proposed amendment(s) will not be entered be		•		
(a) 🗵 they raise new issues that would require further	er consideration and/or search (see NOTE below);		
(b) They raise the issue of new matter (see Note b	,			
(c) they are not deemed to place the application is issues for appeal; and/or	n better form for appeal by mate	rially reducing or simplifying the		
(d) they present additional claims without canceli	ing a corresponding number of f	inally rejected claims.		
NOTE: See Continuation Sheet.				
3. Applicant's reply has overcome the following reject	ion(s):	•		
4.⊠ Newly proposed or amended claim(s) <u>89-91 and 95</u> amendment canceling the non-allowable claim(s).		in a separate, timely filed		
5. The a) affidavit, b) exhibit, or c) request for application in condition for allowance because:		idered but does NOT place the		
6. The affidavit or exhibit will NOT be considered becaused by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were newly		
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we				
The status of the claim(s) is (or will be) as follows:		•		
Claim(s) allowed: <u>84 and 88</u> .				
Claim(s) objected to: <u>76,77,79-81 and 86</u> .		•		
Claim(s) rejected: <u>74,75,78,85 and 87</u> .		•		
Claim(s) withdrawn from consideration: 6-8,11-13,1	16-54 and 61-73.	•		
8. The proposed drawing correction filed on is	a) approved or b) disapp	roved by the Examiner.		
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)				
10.⊠ Other: See Continuation Sheet				
•				
•				
:				

Continuation Sheet (PTO-303)

Application N . 009/165,546

Continuation of 2. NOTE: Newly proposed claim 92 recites "has" which the xamin r is reading as open ended and expands the scope of the correlative claims that were pending upon the issuance of the final rejection. Applicant questions how open ended could this claim be since it requires that the peptide bind to an MHC-Class II DR53 molecule. However, the examiner notes that the open language of peoposed claim 92 could encompass additional amin acids that would inhibit the binding of an amin acid of SEQ ID NO 8, 9 or 10 and also include additional amino acids that bind to an MHC-Class II DR53 molecule.

Furthermore, it is unclear whether the word "defined" in newly added claim 93 is to be interpretted as open or closed language.

Continuation of 10. Other: A proper response to a Final rejection includes the cancellation of non-elected claims...

PATRICK J. NOLAN, PHLD.
PRIMARY EXAMINER

	Application No.	Applicant(s)		
	09/165,546	ALEXANDER ET AL. Art Unit 1644 FOR ALLOWANCE. ation. A proper reply to a h places the application in by filed Request for Continu In the final rejection, whichever g date of the final rejection. HE FINAL REJECTION. See Mile R 1.136(a) and the appropriate originally set in the final Office a ting date of the final rejection, et eriod set forth in of the appeal. See NOTE below); Inally rejected claims. Parate, timely filed amend idered but does NOT place to issues which were newless In the inal rejection in the final rejection, et and the inal rejection in the inal rejection in the appeal. In the final rejection in the final Office a ling date of the final rejection, et all rejection in the inal rejection in the appeal. In the final rejection in the inal office a ling date of the final rejection. In the final rejection in the inal office a ling date of the final rejection. In the final rejection in the inal rejection. In the final rejection, which ever		
Advisory Action	Examiner	Art Unit	<u></u>	
	Amy M. DeCloux	<u> </u>		
-The MAILING DATE of this communicati n appe	ars on the cover sheet with the o	orrespondence address		
THE REPLY FILED 21 August 2002 FAILS TO PLACE Therefore, further action by the applicant is required to avifinal rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	old abandonment of this application at timely filed amendment which	h places the application in	ed	
PERIOD FOR RE	PLY [check either a) or b)]		•	
a) The period for reply expiresmonths from the mailing	g date of the final rejection.	in the second se	Later (*	
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire in ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).	ater than SIX MONTHS from the malling FILED WITHIN TWO MONTHS OF THE	g date of the final rejection. HE FINAL REJECTION. See MPI	EP	
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Office timely filed, may reduce any earned patent term adjustment. See 37 C	if extension and the corresponding amo the shortened statutory period for reply se later than three months after the mai	originally set in the final Office ac	ixtension Gon; or	
1. A Notice of Appeal was filed on (1.73/1). Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFF	Brief must be filed within the part of 1.191(d)), to avoid dismissal of	eriod set forth in f the appeal.		
2. The proposed amendment(s) will not be entered be	acause:	•		
(a) 🖾 they raise new issues that would require furthe	er consideration and/or search (see NOTE below);		
(b) ☐ they raise the issue of new matter (see Note below);				
(c) they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by mate	rially reducing or simplifying	g the	
(d) they present additional claims without canceling	ng a corresponding number of f	inally rejected claims.		
NOTE: See Continuation Sheet.	,	•		
3. Applicant's reply has overcome the following rejecti	on(s):	•	•	
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a so	eparate, timely filed amend	ment	
5. The a) affidavit, b) exhibit, or c) request for application in condition for allowance because:		idered but does NOT place	the	
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were newly	,	
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we	· · · · · · · · · · · · · · · · · · ·		,	
The status of the claim(s) is (or will be) as follows:				
Claim(s) allowed:		•		
Claim(s) objected to:		•		
Claim(s) rejected:				
Claim(s) withdrawn from consideration:			•	
8. The proposed drawing correction filed on is	a) approved or b) disapp	roved by the Examiner.		
9. Note the attached Information Disclosure Statemen	nt(s)(PTO-1449) Paper No(s)			
10. Other:		_		
		•		
		4		

Continuation Sheet (PTO-303)

Application No. 09/165,546

Continuation of 2. NOTE: It is noted that applicant still has not addressed the rejection of claim 87 regarding its recitation of SEQ.ID NO:1, which is a nucleic acid (see the Final rejection mailed 3-14-02 (Paper No. 27)). It is noted that newly proposed base claim 89 and dependent claims 90-92 broad in the scope of claim 74 because claim 89 would not contain the limitation recited in claim 74 that the recited peptide stimulates recognition and proliferation of CD4+ cells, and thus claims 89-92 would reuire further consideration and search. Similarly, n wly proposed claim 95 would also require further consideration and s arch, for the reasons just described. Further it is n ted that the second "an" in the first lin finewly proposed claim 89 should be deleted to be consistent with the plural noun it modifies Furth rit is noted that if claims 61-81 were cancelled, claims 85-87 would ultimately depend from a cancel diclaim (claim 74).

PATRICK J. NOLAN, PH.D.
PRIMARY EXAMINER

1 2/12/02